Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | SBI-0206965 |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
SBI-0206965 is a small molecule that selectively inhibits ULK1, resulting in decreased phosphorylation of ULK1 targets, and potentially leading to increased tumor cell death in combination with mTOR inhibitors (PMID: 26118643, PMID: 30166400, PMID: 32393312). |
| DrugClasses | |
| CAS Registry Number | 1884220-36-3 |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| AZD8055 + SBI-0206965 | AZD8055 SBI-0206965 | 0 | 0 |
| Cabozantinib + SBI-0206965 | Cabozantinib SBI-0206965 | 0 | 0 |
| Crizotinib + SBI-0206965 | Crizotinib SBI-0206965 | 0 | 0 |
| Regorafenib + SBI-0206965 | Regorafenib SBI-0206965 | 0 | 0 |
| Sapanisertib + SBI-0206965 | SBI-0206965 Sapanisertib | 0 | 0 |
| SBI-0206965 | SBI-0206965 | 0 | 0 |
| SBI-0206965 + Sirolimus | SBI-0206965 Sirolimus | 0 | 0 |